Maraviroc (BioDeep_00000399018)
natural product
代谢物信息卡片
4,4-difluoro-N-[(1S)-3-[(1R,5S)-3-[3-methyl-5-(propan-2-yl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]cyclohexane-1-carboxamide
化学式: C29H41F2N5O (513.3279)
中文名称: 马拉维若
谱图信息:
最多检出来源 Escherichia coli(natural_products) 100%
分子结构信息
SMILES: C1=CC=CC(=C1)[C@H](CCN2C3CCC2CC(C3)N4C(=NN=C4C(C)C)C)NC(C5CCC(CC5)(F)F)=O
InChI: InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25?,26-/m0/s1
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors
C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist
D065100 - CCR5 Receptor Antagonists
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
数据库引用编号
14 个数据库交叉引用编号
- ChEBI: CHEBI:184662
- ChEBI: CHEBI:63608
- PubChem: 3002977
- Metlin: METLIN85537
- DrugBank: DB04835
- ChEMBL: CHEMBL1201187
- ChEMBL: CHEMBL584744
- ChEMBL: CHEMBL256907
- MeSH: Maraviroc
- CAS: 2414315-81-2
- CAS: 376348-65-1
- CAS: 376348-65-1, 674782-29-7
- MoNA: CCMSLIB00000078381
- MoNA: CCMSLIB00000078380
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Pooja Singh, Vikas Kumar, Gihwan Lee, Tae Sung Jung, Min Woo Ha, Jong Chan Hong, Keun Woo Lee. Pharmacophore-Oriented Identification of Potential Leads as CCR5 Inhibitors to Block HIV Cellular Entry.
International journal of molecular sciences.
2022 Dec; 23(24):. doi:
10.3390/ijms232416122. [PMID: 36555761] - Takeshi Zoshima, Tomohisa Baba, Yamato Tanabe, Yuko Ishida, Kimihiko Nakatani, Michio Nagata, Naofumi Mukaida, Mitsuhiro Kawano. CCR2- and CCR5-mediated macrophage infiltration contributes to glomerular endocapillary hypercellularity in antibody-induced lupus nephritis.
Rheumatology (Oxford, England).
2022 07; 61(7):3033-3048. doi:
10.1093/rheumatology/keab825. [PMID: 34747459] - Ian M McGowan, Sylvain Chawki, Craig W Hendrix, Peter A Anton, Mark A Marzinke, Rhonda M Brand, Jarret C Engstrom, Lisa C Rohan, Kaleab Z Abebe, Nicola Richardson-Harman, Aaron Siegel, Alex Reinhart, John Steytler, Ronald Stall, Hans Spiegel, Beatrice Chen, Sharon L Achilles, Cindy E Jacobson, Elena Khanukova, Ross D Cranston. A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1\% Gel (the CHARM-03 Study).
AIDS research and human retroviruses.
2022 04; 38(4):269-278. doi:
10.1089/aid.2021.0096. [PMID: 34384282] - Patrick Appiah-Kubi, Emmanuel Amarachi Iwuchukwu, Mahmoud E S Soliman. Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5.
Journal of biomolecular structure & dynamics.
2022; 40(23):13115-13126. doi:
10.1080/07391102.2021.1982006. [PMID: 34569417] - Ronald Rose, Margaret Gartland, Zhufang Li, Nannan Zhou, Mark Cockett, Jagadish Beloor, Max Lataillade, Peter Ackerman, Mark Krystal. Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
AIDS (London, England).
2022 01; 36(1):11-18. doi:
10.1097/qad.0000000000003097. [PMID: 34628442] - Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore. Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants.
HIV research & clinical practice.
2021 12; 23(1):1-8. doi:
NULL. [PMID: 35285786] - Yenisleidys Martínez-Montesinos, Vivian Kourí-Cordellá, Lissette Pérez-Santos, Rui Han, Yanet Pintos-Saavedra, Yoan Alemán-Campos, Yudira Soto-Brito, Yoanna Baños-Morales, Yaniris Caturla-Fernández. Subtype-Dependent Co-receptor Tropism in Cuban HIV-1-Infected Patients: Implications for Maraviroc Treatment.
MEDICC review.
2021 Jul; 23(3-4):29-36. doi:
10.37757/mr2021.v23.n3.6. [PMID: 34516534] - Pei-Chi Chan, Min-Tser Liao, Chieh-Hua Lu, Yu-Feng Tian, Po-Shiuan Hsieh. Targeting inhibition of CCR5 on improving obesity-associated insulin resistance and impairment of pancreatic insulin secretion in high fat-fed rodent models.
European journal of pharmacology.
2021 Jan; 891(?):173703. doi:
10.1016/j.ejphar.2020.173703. [PMID: 33159935] - Stephanie M Matt, Emily A Nickoloff-Bybel, Yi Rong, Kaitlyn Runner, Hannah Johnson, Margaret H O'Connor, Elias K Haddad, Peter J Gaskill. Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV.
Frontiers in immunology.
2021; 12(?):663061. doi:
10.3389/fimmu.2021.663061. [PMID: 34093554] - Jasmin Kuratli, Cory Ann Leonard, Lisbeth Nufer, Hanna Marti, Robert Schoborg, Nicole Borel. Maraviroc, celastrol and azelastine alter Chlamydia trachomatis development in HeLa cells.
Journal of medical microbiology.
2020 Dec; 69(12):1351-1366. doi:
10.1099/jmm.0.001267. [PMID: 33180014] - Mika Okamoto, Masaaki Toyama, Masanori Baba. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
Antiviral research.
2020 10; 182(?):104902. doi:
10.1016/j.antiviral.2020.104902. [PMID: 32739404] - Matthew Weichseldorfer, Yvonne Affram, Alonso Heredia, Yutaka Tagaya, Francesca Benedetti, Davide Zella, Marvin Reitz, Fabio Romerio, Olga S Latinovic. Anti-HIV Activity of Standard Combined Antiretroviral Therapy in Primary Cells Is Intensified by CCR5-Targeting Drugs.
AIDS research and human retroviruses.
2020 10; 36(10):835-841. doi:
10.1089/aid.2020.0064. [PMID: 32623916] - Lenka Tupova, Birgit Hirschmugl, Simona Sucha, Veronika Pilarova, Virág Székely, Éva Bakos, Lucie Novakova, Csilla Özvegy-Laczka, Christian Wadsack, Martina Ceckova. Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2020 Sep; 129(?):110506. doi:
10.1016/j.biopha.2020.110506. [PMID: 32768979] - Gaetano Alfano, Giovanni Guaraldi, Francesco Fontana, Erica Franceschini, Giovanni Dolci, Cristina Mussini, Gianni Cappelli. Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society.
2020 Aug; 22(4):e13294. doi:
10.1111/tid.13294. [PMID: 32294287] - Anas Shamsi, Taj Mohammad, Saleha Anwar, Mohamed F AlAjmi, Afzal Hussain, Md Tabish Rehman, Asimul Islam, Md Imtaiyaz Hassan. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
Bioscience reports.
2020 06; 40(6):. doi:
10.1042/bsr20201256. [PMID: 32441299] - Pierre Calmet, Christophe Cullin, Sandra Cortès, Maylou Vang, Nada Caudy, Rim Baccouch, Jean Dessolin, Nada Taib Maamar, Sophie Lecomte, Bruno Tillier, Isabel D Alves. Cholesterol impacts chemokine CCR5 receptor ligand-binding activity.
The FEBS journal.
2020 06; 287(11):2367-2385. doi:
10.1111/febs.15145. [PMID: 31738467] - Laura Pérez-Martínez, Lourdes Romero, Sandra Muñoz-Galván, Eva M Verdugo-Sivianes, Susana Rubio-Mediavilla, José A Oteo, Amancio Carnero, José-Ramón Blanco. Implications of maraviroc and/or rapamycin in a mouse model of fragility.
Aging.
2020 04; 12(9):8565-8582. doi:
10.18632/aging.103167. [PMID: 32353830] - Cornelia Feiterna-Sperling, Renate Krüger, Alieu Amara, Saye Khoo, Catriona Waitt. Pharmacokinetics of maraviroc in plasma and breastmilk in a treatment-experienced perinatally HIV-1-infected woman.
AIDS (London, England).
2019 12; 33(15):2443-2444. doi:
10.1097/qad.0000000000002360. [PMID: 31764111] - Lenka Tupova, Martina Ceckova, Csilla Ambrus, Ales Sorf, Zuzana Ptackova, Zsuzsanna Gaborik, Frantisek Staud. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.
Drug metabolism and disposition: the biological fate of chemicals.
2019 09; 47(9):954-960. doi:
10.1124/dmd.119.087684. [PMID: 31266750] - Stefania Piconi, Antonella Foschi, Andrea Malagoli, Federica Carli, Stefano Zona, Jovana Milic, Elena Delfina Ricci, Giuliano Rizzardini, Giovanni Guaraldi. Impact of prolonged maraviroc treatment on non-AIDS-related comorbidities in HIV-positive patients: a retrospective cohort study.
The Journal of antimicrobial chemotherapy.
2019 09; 74(9):2723-2731. doi:
10.1093/jac/dkz227. [PMID: 31139818] - Olga S Latinovic, Lauren M Neal, Yutaka Tagaya, Alonso Heredia, Sandra Medina-Moreno, Juan C Zapata, Marvin Reitz, Joseph Bryant, Robert R Redfield. Suppression of Active HIV-1 Infection in CD34+ Hematopoietic Humanized NSG Mice by a Combination of Combined Antiretroviral Therapy and CCR5 Targeting Drugs.
AIDS research and human retroviruses.
2019 08; 35(8):718-728. doi:
10.1089/aid.2018.0305. [PMID: 31099257] - Pavan Kumar Prathipati, Subhra Mandal, Christopher J Destache. A review of CCR5 antibodies against HIV: current and future aspects.
Therapeutic delivery.
2019 02; 10(2):107-112. doi:
10.4155/tde-2018-0072. [PMID: 30729884] - Ian McGowan, Timothy Wilkin, Raphael J Landovitz, Chunyuan Wu, Ying Chen, Mark A Marzinke, Craig W Hendrix, Paul Richardson, Susan H Eshleman, Adriana Andrade, Wairimu Chege, Peter L Anderson, Marybeth McCauley, Jason Farley, Kenneth H Mayer, Peter Anton, Rhonda M Brand, Ross D Cranston, Roy Gulick. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
AIDS (London, England).
2019 02; 33(2):237-246. doi:
10.1097/qad.0000000000002038. [PMID: 30557160] - M Ghannad, M Dennehy, C la Porte, I Seguin, D Tardiff, R Mallick, E Sabri, G Zhang, S Kanji, D W Cameron. A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.
PloS one.
2019; 14(10):e0223969. doi:
10.1371/journal.pone.0223969. [PMID: 31647836] - Måns Ekelöf, Kenneth P Garrard, Rika Judd, Elias P Rosen, De-Yu Xie, Angela D M Kashuba, David C Muddiman. Evaluation of Digital Image Recognition Methods for Mass Spectrometry Imaging Data Analysis.
Journal of the American Society for Mass Spectrometry.
2018 Dec; 29(12):2467-2470. doi:
10.1007/s13361-018-2073-0. [PMID: 30324263] - Asaff Harel, Sam Horng, Tarah Gustafson, Anil Ramineni, Rebecca Straus Farber, Michelle Fabian. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia.
Journal of neurovirology.
2018 10; 24(5):652-655. doi:
10.1007/s13365-018-0657-x. [PMID: 29987583] - Cynthia N Schreiner, Charles E Ahlfors, Ronald J Wong, David K Stevenson, Diana F Clarke, Mark Mirochnick. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding.
The Pediatric infectious disease journal.
2018 09; 37(9):908-909. doi:
10.1097/inf.0000000000002011. [PMID: 29561509] - Kathleen L Vincent, John A Moss, Mark A Marzinke, Craig W Hendrix, Peter A Anton, Richard B Pyles, Kate M Guthrie, Lauren Dawson, Trevelyn J Olive, Irina Butkyavichene, Scott A Churchman, John M Cortez, Rob Fanter, Manjula Gunawardana, Christine S Miller, Flora Yang, Rochelle K Rosen, Sara E Vargas, Marc M Baum. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
PLoS medicine.
2018 09; 15(9):e1002655. doi:
10.1371/journal.pmed.1002655. [PMID: 30265679] - Egidio Brocca-Cofano, Cuiling Xu, Katherine S Wetzel, Mackenzie L Cottrell, Benjamin B Policicchio, Kevin D Raehtz, Dongzhu Ma, Tammy Dunsmore, George S Haret-Richter, Karam Musaitif, Brandon F Keele, Angela D Kashuba, Ronald G Collman, Ivona Pandrea, Cristian Apetrei. Marginal Effects of Systemic CCR5 Blockade with Maraviroc on Oral Simian Immunodeficiency Virus Transmission to Infant Macaques.
Journal of virology.
2018 09; 92(17):. doi:
10.1128/jvi.00576-18. [PMID: 29925666] - Borja Mora-Peris, George Bouliotis, Kulasegaram Ranjababu, Amanda Clarke, Frank A Post, Mark Nelson, Laura Burgess, Juan Tiraboschi, Saye Khoo, Steve Taylor, Deborah Ashby, Alan Winston. Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals.
AIDS (London, England).
2018 05; 32(8):1007-1015. doi:
10.1097/qad.0000000000001786. [PMID: 29438199] - Jun Jin, Fanny Momboisse, Gaelle Boncompain, Florian Koensgen, Zhicheng Zhou, Nelia Cordeiro, Fernando Arenzana-Seisdedos, Franck Perez, Bernard Lagane, Esther Kellenberger, Anne Brelot. CCR5 adopts three homodimeric conformations that control cell surface delivery.
Science signaling.
2018 05; 11(529):. doi:
10.1126/scisignal.aal2869. [PMID: 29739880] - Claire Pressiat, Déborah Hirt, Jean-Marc Treluyer, Yi Zheng, Philippe Morlat, Alice Naqvi, Laurent Tran, Jean-Paul Viard, Véronique Avettand-Fenoel, Christine Rouzioux, Laurence Meyer, Antoine Cheret. Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
The Journal of antimicrobial chemotherapy.
2018 04; 73(4):1020-1024. doi:
10.1093/jac/dkx498. [PMID: 29365125] - T J Barber, A Imaz, M Boffito, J Niubó, A Pozniak, R Fortuny, J Alonso, N Davies, S Mandalia, D Podzamczer, B Gazzard. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Journal of neurovirology.
2018 02; 24(1):98-105. doi:
10.1007/s13365-017-0600-6. [PMID: 29280108] - Antoine Chaillon, Sara Gianella, Steven M Lada, Josué Perez-Santiago, Parris Jordan, Caroline Ignacio, Maile Karris, Douglas D Richman, Sanjay R Mehta, Susan J Little, Joel O Wertheim, Davey M Smith. Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc.
Journal of virology.
2018 02; 92(3):. doi:
10.1128/jvi.01589-17. [PMID: 29142136] - Sanjay Pujari, Sunil Gaikwad, Vivek Bele, Kedar Joshi, Digamber Dabhade. High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.
Journal of the International Association of Providers of AIDS Care.
2018 Jan; 17(?):2325958218759211. doi:
10.1177/2325958218759211. [PMID: 29473485] - Cinzia Sanna, Monica Scognamiglio, Antonio Fiorentino, Angela Corona, Vittoria Graziani, Alessia Caredda, Pierluigi Cortis, Mariofilippo Montisci, Elisa Rita Ceresola, Filippo Canducci, Ferruccio Poli, Enzo Tramontano, Francesca Esposito. Prenylated phloroglucinols from Hypericum scruglii, an endemic species of Sardinia (Italy), as new dual HIV-1 inhibitors effective on HIV-1 replication.
PloS one.
2018; 13(3):e0195168. doi:
10.1371/journal.pone.0195168. [PMID: 29601601] - S L Pett, J Amin, A Horban, J Andrade-Villanueva, M Losso, N Porteiro, J S Madero, W Belloso, E Tu, D Silk, A Kelleher, R Harrigan, A Clark, W Sugiura, M Wolff, J Gill, J Gatell, A Clarke, K Ruxrungtham, T Prazuck, R Kaiser, I Woolley, J Alberto Arnaiz, D Cooper, J K Rockstroh, P Mallon, S Emery. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.
HIV medicine.
2018 01; 19(1):65-71. doi:
10.1111/hiv.12532. [PMID: 28703491] - Amare Worku Kalu, Nigus Fikrie Telele, Shambhu G Aralaguppe, Solomon Gebre-Selassie, Daniel Fekade, Gaetano Marrone, Anders Sonnerborg. Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods.
Current HIV research.
2018; 16(2):113-120. doi:
10.2174/1570162x16666180515124836. [PMID: 29766813] - Marilyn Lewis, Julie Mori, Jonathan Toma, Mike Mosley, Wei Huang, Paul Simpson, Roy Mansfield, Charles Craig, Elna van der Ryst, David L Robertson, Jeannette M Whitcomb, Mike Westby. Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
PloS one.
2018; 13(12):e0204099. doi:
10.1371/journal.pone.0204099. [PMID: 30586365] - Jacqueline K Flynn, Paula Ellenberg, Renee Duncan, Anne Ellett, Jingling Zhou, Jasminka Sterjovski, Kieran Cashin, Katharina Borm, Lachlan R Gray, Marilyn Lewis, Becky Jubb, Mike Westby, Benhur Lee, Sharon R Lewin, Melissa Churchill, Michael Roche, Paul R Gorry. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
AIDS research and human retroviruses.
2017 12; 33(12):1220-1235. doi:
10.1089/aid.2017.0097. [PMID: 28797170] - Minh P Lê, Linda Belarbi, Marie-Laure Chaix, Emmanuel Dulioust, Nadia Mahjoub, Dominique Salmon, Jean-Paul Viard, Claudine Duvivier, Gilles Peytavin, Odile Launay, Jade Ghosn. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
The Journal of antimicrobial chemotherapy.
2017 Nov; 72(11):3167-3171. doi:
10.1093/jac/dkx275. [PMID: 28961979] - David M Asmuth, Corbin G Thompson, Tae-Wook Chun, Zhong-Min Ma, Surinder Mann, Talia Sainz, Sergio Serrano-Villar, Netanya S Utay, Juan Carlos Garcia, Paolo Troia-Cancio, Richard B Pollard, Christopher J Miller, Alan Landay, Angela D Kashuba. Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
The Journal of infectious diseases.
2017 10; 216(7):813-818. doi:
10.1093/infdis/jix418. [PMID: 28968888] - Roy M Gulick, Timothy J Wilkin, Ying Q Chen, Raphael J Landovitz, K Rivet Amico, Alicia M Young, Paul Richardson, Mark A Marzinke, Craig W Hendrix, Susan H Eshleman, Ian McGowan, Leslie M Cottle, Adriana Andrade, Cheryl Marcus, Karin L Klingman, Wairimu Chege, Alex R Rinehart, James F Rooney, Philip Andrew, Robert A Salata, Marc Siegel, Yukari C Manabe, Ian Frank, Ken Ho, Jorge Santana, Joanne D Stekler, Shobha Swaminathan, Marybeth McCauley, Sally Hodder, Kenneth H Mayer. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.
Annals of internal medicine.
2017 Sep; 167(6):384-393. doi:
10.7326/m17-0520. [PMID: 28828489] - Connie J Kim, Rodney Rousseau, Sanja Huibner, Colin Kovacs, Erika Benko, Kamnoosh Shahabi, Gabor Kandel, Mario Ostrowski, Rupert Kaul. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
AIDS (London, England).
2017 07; 31(11):1529-1534. doi:
10.1097/qad.0000000000001515. [PMID: 28463882] - Amedeo Ferdinando Capetti, Mariangela Micale, Laura Carenzi, Fosca Niero, Simona Landonio, Stefania Vimercati, Gianfranco Dedivitiis, Giuliano Rizzardini. Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugs: A retrospective study.
Medicine.
2017 Feb; 96(7):e5728. doi:
10.1097/md.0000000000005728. [PMID: 28207500] - Barbara Rossetti, Roberta Gagliardini, Genny Meini, Gaetana Sterrantino, Vincenzo Colangeli, Maria Carla Re, Alessandra Latini, Manuela Colafigli, Francesca Vignale, Stefano Rusconi, Valeria Micheli, Antonio Di Biagio, Giancarlo Orofino, Valeria Ghisetti, Alessandra Fantauzzi, Vincenzo Vullo, Pierfrancesco Grima, Daniela Francisci, Claudio Mastroianni, Andrea Antinori, Michele Trezzi, Lucia Lisi, Pierluigi Navarra, Benedetta Canovari, Antonella D'Arminio Monforte, Silvia Lamonica, Alessandro D'Avino, Maurizio Zazzi, Simona Di Giambenedetto, Andrea De Luca. Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
PloS one.
2017; 12(11):e0187393. doi:
10.1371/journal.pone.0187393. [PMID: 29161288] - Marco Ripa, Manuela Pogliaghi, Stefania Chiappetta, Silvia Nozza, Alessandro Soria, Giacomo Coppalini, Cristina Rovelli, Giuseppe Tambussi. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
2016 12; 85(?):86-89. doi:
10.1016/j.jcv.2016.10.016. [PMID: 27865174] - Teresa L Parsons, Mark A Marzinke. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Journal of pharmaceutical and biomedical analysis.
2016 Nov; 131(?):333-344. doi:
10.1016/j.jpba.2016.08.016. [PMID: 27632783] - Julie Fox, Juan M Tiraboschi, Carolina Herrera, Laura Else, Deirdre Egan, Laura Dickinson, Akil Jackson, Natalia Olejniczak, David Back, Saye Khoo, Robin Shattock, Marta Boffito. Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis.
Journal of acquired immune deficiency syndromes (1999).
2016 11; 73(3):252-257. doi:
10.1097/qai.0000000000001108. [PMID: 27727157] - Pierre Pradat, Jacques Durant, Corinne Brochier, Mary-Anne Trabaud, Jacqueline Cottalorda-Dufayard, Jacques Izopet, François Raffi, Frédéric Lucht, Marie-Claude Gagnieu, Caroline Gatey, Christine Jacomet, Matteo Vassallo, Pierre Dellamonica, Laurent Cotte. Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
The Journal of antimicrobial chemotherapy.
2016 11; 71(11):3235-3241. doi:
10.1093/jac/dkw273. [PMID: 27432606] - Ellen S Chan, Alan L Landay, Todd T Brown, Heather J Ribaudo, Paria Mirmonsef, Igho Ofotokun, M Neale Weitzmann, Jeffrey Martinson, Karin L Klingman, Joseph J Eron, Carl J Fichtenbaum, Jill Plants, Babafemi O Taiwo. Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
AIDS (London, England).
2016 08; 30(13):2091-7. doi:
10.1097/qad.0000000000001181. [PMID: 27281061] - Mackenzie L Cottrell, Heather M A Prince, Andrew Allmon, Katie R Mollan, Michael G Hudgens, Craig Sykes, Nicole White, Stephanie Malone, Evan S Dellon, Ryan D Madanick, Nicholas J Shaheen, Kristine B Patterson, Angela D M Kashuba. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design.
Journal of acquired immune deficiency syndromes (1999).
2016 08; 72(5):498-506. doi:
10.1097/qai.0000000000000996. [PMID: 26999532] - Sarah Lilian Pett, Janaki Amin, Andrejz Horban, Jaime Andrade-Villanueva, Marcelo Losso, Norma Porteiro, Juan Sierra Madero, Waldo Belloso, Elise Tu, David Silk, Anthony Kelleher, Richard Harrigan, Andrew Clark, Wataru Sugiura, Marcelo Wolff, John Gill, Jose Gatell, Martin Fisher, Amanda Clarke, Kiat Ruxrungtham, Thierry Prazuck, Rolf Kaiser, Ian Woolley, Juan Alberto Arnaiz, David Cooper, Jürgen K Rockstroh, Patrick Mallon, Sean Emery. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2016 07; 63(1):122-32. doi:
10.1093/cid/ciw207. [PMID: 27048747] - Sean C Patro, Livio Azzoni, Jocelin Joseph, Matthew G Fair, Juan G Sierra-Madero, Mohammed S Rassool, Ian Sanne, Luis J Montaner. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation.
Journal of leukocyte biology.
2016 07; 100(1):223-31. doi:
10.1189/jlb.5ab0915-406r. [PMID: 26609048] - Charlene S Dezzutti, Nicola Richardson-Harman, Lisa C Rohan, Mark A Marzinke, Craig J Hoesley, Lori Panther, Sherri Johnson, Jeremy P Nuttall, Annalene Nel, Beatrice A Chen. Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial.
Medicine.
2016 Jul; 95(28):e4174. doi:
10.1097/md.0000000000004174. [PMID: 27428211] - Anna K Blakney, Yonghou Jiang, Dale Whittington, Kim A Woodrow. Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Jul; 1025(?):110-8. doi:
10.1016/j.jchromb.2016.04.048. [PMID: 27236000] - Samatchaya Boonchawalit, Shigeyoshi Harada, Noriko Shirai, Hiroyuki Gatanaga, Shinichi Oka, Shuzo Matsushita, Kazuhisa Yoshimura. Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.
Japanese journal of infectious diseases.
2016 May; 69(3):236-43. doi:
10.7883/yoken.jjid.2015.310. [PMID: 26166507] - R Ramanathan, Y Jiang, B Read, S Golan-Paz, K A Woodrow. Biophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.
Acta biomaterialia.
2016 05; 36(?):122-31. doi:
10.1016/j.actbio.2016.02.034. [PMID: 26947382] - Nadia Ahmed, Chinyere Okoli, Jonathan Ainsworth. Ineffective central nervous system HIV suppression of once-a-day maraviroc and ritonavir-boosted darunavir dual therapy: four case reports.
International journal of STD & AIDS.
2016 Mar; 27(4):321-2. doi:
10.1177/0956462415584486. [PMID: 25969439] - Yanqin Ren, Liangzhu Li, Yanmin Wan, Wei Wang, Jing Wang, Jian Chen, Qiang Wei, Chuan Qin, Jianqing Xu, Xiaoyan Zhang. Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Journal of acquired immune deficiency syndromes (1999).
2016 Feb; 71(2):121-9. doi:
10.1097/qai.0000000000000851. [PMID: 26413849] - Joseph Scott, Jonathan Underwood, Lucy J Garvey, Borja Mora-Peris, Alan Winston. A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.
The British journal of radiology.
2016; 89(1060):20150979. doi:
10.1259/bjr.20150979. [PMID: 26954329] - Sergio Serrano-Villar, Talia Sainz, Zhong-Min Ma, Netanya S Utay, Tae-Wook Chun, Tae Wook-Chun, Surinder Mann, Angela D Kashuba, Basile Siewe, Anthony Albanese, Paolo Troia-Cancio, Elizabeth Sinclair, Anoma Somasunderam, Tammy Yotter, Steven G Deeks, Alan Landay, Richard B Pollard, Christopher J Miller, Santiago Moreno, David M Asmuth. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
PLoS pathogens.
2016 Jan; 12(1):e1005381. doi:
10.1371/journal.ppat.1005381. [PMID: 26795282] - S F L van Lelyveld, J Symons, P van Ham, B J Connell, M Nijhuis, A M J Wensing, A I M Hoepelman. Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients.
International journal of antimicrobial agents.
2016 Jan; 47(1):84-90. doi:
10.1016/j.ijantimicag.2015.09.013. [PMID: 26585497] - Charles W Dobard, Andrew Taylor, Sunita Sharma, Peter L Anderson, Lane R Bushman, Dinh Chuong, Chou-Pong Pau, Debra Hanson, Lin Wang, J Gerardo Garcia-Lerma, Ian McGowan, Lisa Rohan, Walid Heneine. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
The Journal of infectious diseases.
2015 Dec; 212(12):1988-95. doi:
10.1093/infdis/jiv334. [PMID: 26071566] - Beatrice A Chen, Lori Panther, Mark A Marzinke, Craig W Hendrix, Craig J Hoesley, Ariane van der Straten, Marla J Husnik, Lydia Soto-Torres, Annalene Nel, Sherri Johnson, Nicola Richardson-Harman, Lorna K Rabe, Charlene S Dezzutti. Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings: A Double-Blind Randomized Trial.
Journal of acquired immune deficiency syndromes (1999).
2015 Nov; 70(3):242-9. doi:
10.1097/qai.0000000000000702. [PMID: 26034880] - Josep Coll, José Moltó, Jaume Boix, Elisabet Gómez-Mora, Laura Else, Elisabet García, Roger Paredes, Dan Ouchi, Antonio Carrillo, Roser Escrig, David Back, Bonaventura Clotet, Cecilia Cabrera. Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers.
AIDS (London, England).
2015 Oct; 29(16):2149-54. doi:
10.1097/qad.0000000000000769. [PMID: 26544579] - Anthony R Cillo, Benedict B Hilldorfer, Christina M Lalama, John E McKinnon, Robert W Coombs, Allan R Tenorio, Lawrence Fox, Rajesh T Gandhi, Heather Ribaudo, Judith S Currier, Roy M Gulick, Timothy J Wilkin, John W Mellors. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
AIDS (London, England).
2015 Oct; 29(16):2121-9. doi:
10.1097/qad.0000000000000810. [PMID: 26544577] - José-Ramón Blanco, David Arroyo-Manzano, John F Rojas-Liévano, Manuel Crespo, Isa Bravo, Juan Pasquau, Miguel Garcia Del Toro, Cristina Herrero, Antonio Rivero, Santiago Moreno, Josep Maria Llibre. The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
AIDS research and human retroviruses.
2015 Sep; 31(9):893-7. doi:
10.1089/aid.2015.0016. [PMID: 26059859] - Josep M Llibre, Antonio Rivero, Jhon F Rojas, Miguel Garcia Del Toro, Cristina Herrero, David Arroyo, Juan A Pineda, Juan Pasquau, Mar Masiá, Manel Crespo, José R Blanco, Santiago Moreno. Safety, efficacy and indications of prescription of maraviroc in clinical practice: Factors associated with clinical outcomes.
Antiviral research.
2015 Aug; 120(?):79-84. doi:
10.1016/j.antiviral.2015.05.001. [PMID: 25977241] - Minh Patrick Lê, Cathia Soulié, Lambert Assoumou, Marc-Antoine Valantin, Claudine Duvivier, Julie Chas, Diane Ponscarme, Anne-Geneviève Marcelin, Vincent Calvez, Christine Katlama, Gilles Peytavin. Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
The Journal of antimicrobial chemotherapy.
2015 Aug; 70(8):2418-20. doi:
10.1093/jac/dkv113. [PMID: 25917348] - Roberto Manfredi, Leonardo Calza, Ginevra Marinacci, Alessandra Cascavilla, Vincenzo Colangeli, Caterina Salvadori, Giulia Martelli, Lucia Appolloni, Cristina Puggioli, Pierluigi Viale. A prospective evaluation of maraviroc administration in patients with advanced HIV disease and multiple comorbidities: focus on efficacy and tolerability issues.
Le infezioni in medicina.
2015 Mar; 23(1):36-43. doi:
NULL. [PMID: 25819049] - Jing Yuan, Han-yun Ren, Yong-jin Shi, Wei Liu. Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.
Inflammation research : official journal of the European Histamine Research Society ... [et al.].
2015 Feb; 64(2):137-44. doi:
10.1007/s00011-014-0793-6. [PMID: 25556580] - M Surdo, C Alteri, M C Puertas, P Saccomandi, L Parrotta, L Swenson, D Chapman, G Costa, A Artese, E Balestra, S Aquaro, S Alcaro, M Lewis, B Clotet, R Harrigan, H Valdez, V Svicher, C F Perno, J Martinez-Picado, F Ceccherini-Silberstein. Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
2015 Jan; 21(1):103.e1-6. doi:
10.1016/j.cmi.2014.08.002. [PMID: 25636934] - Steven F L van Lelyveld, Julia Drylewicz, Maaike Krikke, Ellen M Veel, Sigrid A Otto, Clemens Richter, Robin Soetekouw, Jan M Prins, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Annemarie M J Wensing, Monique Nijhuis, José A M Borghans, Kiki Tesselaar, Andy I M Hoepelman. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.
PloS one.
2015; 10(7):e0132430. doi:
10.1371/journal.pone.0132430. [PMID: 26208341] - Alessandro Schipani, David Back, Andrew Owen, Gerry Davies, Saye Khoo, Marco Siccardi. Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
Clinical pharmacokinetics.
2015 Jan; 54(1):107-16. doi:
10.1007/s40262-014-0184-8. [PMID: 25245943] - Mariangela Cavarelli, Lara Mainetti, Angela Rosa Pignataro, Alba Bigoloni, Monica Tolazzi, Andrea Galli, Silvia Nozza, Antonella Castagna, Michela Sampaolo, Enzo Boeri, Gabriella Scarlatti. Complexity and dynamics of HIV-1 chemokine receptor usage in a multidrug-resistant adolescent.
AIDS research and human retroviruses.
2014 Dec; 30(12):1243-50. doi:
10.1089/aid.2014.0124. [PMID: 25275490] - Lishomwa C Ndhlovu, Tracie Umaki, Glen M Chew, Dominic C Chow, Melissa Agsalda, Kalpana J Kallianpur, Robert Paul, Guangxiang Zhang, Erika Ho, Nancy Hanks, Beau Nakamoto, Bruce T Shiramizu, Cecilia M Shikuma. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
Journal of neurovirology.
2014 Dec; 20(6):571-82. doi:
10.1007/s13365-014-0279-x. [PMID: 25227930] - Yanhui Lu, Edward J Fuchs, Craig W Hendrix, Namandjé N Bumpus. CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.
Drug metabolism and disposition: the biological fate of chemicals.
2014 Nov; 42(11):1796-802. doi:
10.1124/dmd.114.060194. [PMID: 25117426] - A Calcagno, S Nozza, M Simiele, M G Milia, S Chiappetta, A D'Avolio, V Ghisetti, A Lazzarin, G Di Perri, S Bonora. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2014 Sep; 69(9):2586-8. doi:
10.1093/jac/dku142. [PMID: 24812593] - Milena Veselinovic, Kuo-Hsiung Yang, Jonathan LeCureux, Craig Sykes, Leila Remling-Mulder, Angela D M Kashuba, Ramesh Akkina. HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Virology.
2014 Sep; 464-465(?):253-263. doi:
10.1016/j.virol.2014.07.008. [PMID: 25105490] - J Macías, E Recio, M Márquez, C García, P Jiménez, D Merino, L Muñoz, J Pasquau, G Ojeda, P Bancalero, N Chueca, J A Pineda. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
HIV medicine.
2014 Aug; 15(7):417-24. doi:
10.1111/hiv.12129. [PMID: 24580801] - Ana Treviño, Vicente Soriano, Eva Poveda, Patricia Parra, Teresa Cabezas, Estrella Caballero, Lourdes Roc, Carmen Rodríguez, Jose M Eiros, Mariola Lopez, Carmen De Mendoza. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load.
The Journal of antimicrobial chemotherapy.
2014 Aug; 69(8):2191-4. doi:
10.1093/jac/dku119. [PMID: 24788659] - Kazuhisa Yoshimura, Shigeyoshi Harada, Samatchaya Boonchawalit, Yoko Kawanami, Shuzo Matsushita. Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.
The Journal of general virology.
2014 Aug; 95(Pt 8):1816-1826. doi:
10.1099/vir.0.062885-0. [PMID: 24795449] - Daniela Francisci, Emanuela Falcinelli, Silvia Baroncelli, Eleonora Petito, Enisia Cecchini, Liliana Elena Weimer, Marco Floridia, Paolo Gresele, Franco Baldelli. Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.
Scandinavian journal of infectious diseases.
2014 Jun; 46(6):466-70. doi:
10.3109/00365548.2014.898332. [PMID: 24738757] - Marco Simiele, Lorena Baietto, Alessio Audino, Mauro Sciandra, Stefano Bonora, Giovanni Di Perri, Antonio D'Avolio. A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma.
Journal of pharmaceutical and biomedical analysis.
2014 Jun; 94(?):65-70. doi:
10.1016/j.jpba.2014.01.031. [PMID: 24552643] - Christine Katlama, Lambert Assoumou, Marc-Antoine Valantin, Cathia Soulié, Claudine Duvivier, Laetitia Chablais, Sami Kolta, Gilles Pialoux, Patrick Mercié, Anne Simon, Dominique Costagliola, Gilles Peytavin, Anne-Genevieve Marcelin. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
The Journal of antimicrobial chemotherapy.
2014 Jun; 69(6):1648-52. doi:
10.1093/jac/dkt536. [PMID: 24535278] - Martin Markowitz, Teresa H Evering, Donald Garmon, Marina Caskey, Melissa La Mar, Kristina Rodriguez, Vincent Sahi, Sarah Palmer, Nicole Prada, Hiroshi Mohri. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999).
2014 Jun; 66(2):140-7. doi:
10.1097/qai.0000000000000111. [PMID: 24457632] - Joshua F Emory, Lauren A Seserko, Mark A Marzinke. Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.
Clinica chimica acta; international journal of clinical chemistry.
2014 Apr; 431(?):198-205. doi:
10.1016/j.cca.2014.02.008. [PMID: 24561264] - Manoli Vourvahis, Anna Plotka, Constantino Kantaridis, Annie Fang, Jayvant Heera. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999).
2014 Apr; 65(5):564-70. doi:
10.1097/qai.0000000000000090. [PMID: 24346637] - David A Cooper, Jayvant Heera, Prudence Ive, Mariette Botes, Edwin Dejesus, Robert Burnside, Nathan Clumeck, Sharon Walmsley, Adriano Lazzarin, Geoffrey Mukwaya, Michael Saag, Elna van Der Ryst. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
AIDS (London, England).
2014 Mar; 28(5):717-25. doi:
10.1097/qad.0000000000000131. [PMID: 24983542] - Maria C Puertas, Marta Massanella, Josep M Llibre, Monica Ballestero, Maria J Buzon, Dan Ouchi, Anna Esteve, Jaume Boix, Christian Manzardo, Josep M Miró, Josep M Gatell, Bonaventura Clotet, Julià Blanco, Javier Martinez-Picado. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
AIDS (London, England).
2014 Jan; 28(3):325-34. doi:
10.1097/qad.0000000000000066. [PMID: 24185044] - Manoli Vourvahis, Anna Plotka, Laure Mendes da Costa, Annie Fang, Jayvant Heera. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Antimicrobial agents and chemotherapy.
2013 Dec; 57(12):6158-64. doi:
10.1128/aac.01098-13. [PMID: 24080663] - Zoubir Djerada, Catherine Feliu, Claire Tournois, Damien Vautier, Laurent Binet, Arnaud Robinet, Hélène Marty, Claire Gozalo, Denis Lamiable, Hervé Millart. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Journal of pharmaceutical and biomedical analysis.
2013 Dec; 86(?):100-11. doi:
10.1016/j.jpba.2013.08.002. [PMID: 23995753] - Kathleen M Kelly, Sarah E Beck, Kelly A Metcalf Pate, Suzanne E Queen, Jamie L Dorsey, Robert J Adams, Lindsay B Avery, Walter Hubbard, Patrick M Tarwater, Joseph L Mankowski. Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain.
AIDS (London, England).
2013 Nov; 27(18):F21-8. doi:
10.1097/qad.0000000000000074. [PMID: 24051706] - Isabella Bon, Alberto Clò, Marco Borderi, Vincenzo Colangeli, Leonardo Calza, Silvia Morini, Anna Miserocchi, Monica Cricca, Davide Gibellini, Maria Carla Re. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2013 Oct; 17(10):e875-82. doi:
10.1016/j.ijid.2013.02.020. [PMID: 23597487] - Babafemi Taiwo, Edward P Acosta, Patrick Ryscavage, Baiba Berzins, Darlene Lu, Jay Lalezari, Jose Castro, Oluwatoyin Adeyemi, Daniel R Kuritzkes, Joseph J Eron, Athe Tsibris, Susan Swindells. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
Journal of acquired immune deficiency syndromes (1999).
2013 Oct; 64(2):167-73. doi:
10.1097/qai.0b013e3182a03d95. [PMID: 23797691] - Rachel A McGovern, Jori Symons, Art F Y Poon, P Richard Harrigan, Steven F L van Lelyveld, Andy I M Hoepelman, Petra M van Ham, Winnie Dong, Annemarie M J Wensing, Monique Nijhuis. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
The Journal of antimicrobial chemotherapy.
2013 Sep; 68(9):2007-14. doi:
10.1093/jac/dkt153. [PMID: 23677920] - Ivana Massud, Wutyi Aung, Amy Martin, Shanon Bachman, James Mitchell, Rachael Aubert, Theodros Solomon Tsegaye, Ellen Kersh, Chou-Pong Pau, Walid Heneine, J Gerardo García-Lerma. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.
Journal of virology.
2013 Aug; 87(16):8952-61. doi:
10.1128/jvi.01204-13. [PMID: 23740994] - Anthony Kebira Nyamache, Anne W T Muigai, Zipporah Ng'ang'a, Samoel A Khamadi. Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.
AIDS research and human retroviruses.
2013 Aug; 29(8):1105-9. doi:
10.1089/aid.2012.0284. [PMID: 23617327]
